11 people already started in trial atNYC site, son starts trial with first dosage on Oct 23. Dr. Landau reports no toxicity problems with the first 11 patients to this point. I know it is still early but sounds very promising.
Phase I, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis. My son has Amyloidosis and on Friday got notice of acceptance. I bought this stock after it was spun off from ELN @ 6.24 because of this drug. It looks like this will be a big winner if drug works. This disease is a very debilitating disease with those who get it have usually very little chance of living more than 2yrs. Hope it can be successful for my sons sake. When I told his doctors about this trial they didn't know anything about it. They were excited about it after doing their research. I know the doctor I talked to was buying this stock and I believe its move up is because of passing the word around. Doctor actually thanked me for info because he said they don't ever get info about trials and he is a specialist on Amyloidosis at University of Pennsylvania. The only thing is that it will be another 3 to 4 years before trials end. Sorry I didn't buy more, never thought it would move up this quick. Good luck to all.